A Study to Investigate LYL797 in Adults With Solid Tumors

L

Lyell Immunopharma

Status and phase

Enrolling
Phase 1

Conditions

Relapsed Cancer
NSCLC, Recurrent
NSCLC Stage IV
TNBC - Triple-Negative Breast Cancer
Non Small Cell Lung Cancer
Non-Small Cell Carcinoma of Lung, TNM Stage 4
Recurrent NSCLC
Non Small Cell Lung Cancer Metastatic
Advanced Lung Carcinoma
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Recurrent Breast Cancer
Relapse/Recurrence
NSCLC
Advanced Breast Cancer

Treatments

Biological: LYL797

Study type

Interventional

Funder types

Industry

Identifiers

NCT05274451
LYL797-101

Details and patient eligibility

About

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.

Full description

This Phase 1, single-arm, open-label, multi-center, dose-escalation and -expansion study will evaluate the safety and tolerability of LYL797, ROR1-targeting CAR T cells, in adults with relapsed and/or refractory ROR1+ triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). The dose-escalation phase includes TNBC and NSCLC patients, and will investigate 4 dose levels to determine the recommended Phase 2 dose (RP2D). The dose-expansion phase will enroll both TNBC and NSCLC patients at the RP2D.

Enrollment

54 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* ≥ 18 years of age at time of informed consent * Histologically confirmed TNBC or NSCLC that is relapsed or refractory, metastatic or locally advanced and unresectable that is ROR1+ by central laboratory immunohistochemistry (IHC) * Measurable disease including a target lesion and an additional lesion for biopsy * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Adequate organ and marrow function * Women of childbearing potential must have a negative pregnancy test at screening * All participants must agree to practice highly effective methods of contraception

Exclusion criteria

* Prior treatment with any adoptive T-cell therapy or anti-ROR1 therapy * Prior solid organ transplantation * Active, untreated brain metastasis or leptomeningeal disease; stable, treated brain involvement by disease is allowed * Untreated or active infection at the time of screening or leukapheresis * HIV-positive, HTLV-1-positive, active acute or chronic HBV or HCV, or active tuberculosis * Impaired cardiac function or clinically significant cardiac disease * Uncontrolled pleural or pericardial effusion * Systemic corticosteroids or other immunosuppressive medications within 14 days of leukapheresis * Required chronic anticoagulation, such as warfarin, low molecular weight heparin, or Factor Xa inhibitors * Pregnant or lactating/nursing women

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

54 participants in 1 patient group

Experimental LYL797
Experimental group
Description:
ROR1-targeted CAR T cells
Treatment:
Biological: LYL797

Trial contacts and locations

18

Loading...

Central trial contact

Jackie Walling, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems